Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

80.61USD
22 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$80.61
Open
--
Day's High
--
Day's Low
--
Volume
86
Avg. Vol
1,839,461
52-wk High
$123.25
52-wk Low
$74.14

Chart for

About

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology... (more)

Overall

Beta: 1.88
Market Cap(Mil.): $108,911.00
Shares Outstanding(Mil.): 782.35
Dividend: --
Yield (%): --

Financials

  CELG.OQ Industry Sector
P/E (TTM): 43.29 30.90 33.64
EPS (TTM): 3.22 -- --
ROI: 10.08 14.75 14.27
ROE: 37.19 16.25 15.99

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

UPDATE 1-Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

Agios names former Celgene executive Jacqualyn Fouse as next CEO

Sept 4 Agios Pharmaceuticals Inc on Tuesday said former Celgene Corp executive Jacqualyn Fouse would be its next chief executive officer, replacing longtime CEO David Schenkein.

04 Sep 2018

U.S. health secretary says agency can eliminate drug rebates

WASHINGTON U.S. Health and Human Services Secretary Alex Azar said it was within his agency's power to eliminate rebates on prescription drug purchases, a key element of the Trump administration's plan to lower prescription medicine costs. | Video

20 Aug 2018

Celgene profit tops expectations, will limit future price hikes

Celgene Corp on Thursday posted better-than-expected second quarter profit, powered by a 21 percent jump in sales of its blockbuster cancer drug Revlimid, and the U.S. biotech promised to limit future price increases on its medicines. The company joined several rivals in bowing to pressure from the administration of U.S. President Donald Trump to rein in rising costs of prescription drugs to U.S. patients.

26 Jul 2018

UPDATE 2-Celgene profit tops expectations, will limit future price hikes

* Revlimid sales beat Wall Street estimates (Adds company, analyst comment, background, share movement)

26 Jul 2018

Celgene quarterly profit drops 5 pct

July 26 U.S. drugmaker Celgene Corp reported a 5 percent drop in quarterly profit on Thursday, hurt by higher expenses.

26 Jul 2018

BRIEF-Celgene Corp Says Phase III Impassion130 Study Met Co-Primary Endpoint Of Progression-Free Survival

* ANTI-PD-L1 IMMUNOTHERAPY PLUS ABRAXANE® SIGNIFICANTLY REDUCED THE RISK OF DISEASE WORSENING OR DEATH IN PATIENTS WITH METASTATIC OR LOCALLY ADVANCED TRIPLE NEGATIVE BREAST CANCER IN PHASE III IMPASSION130 STUDY

10 Jul 2018

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

04 May 2018

UPDATE 3-Celgene profit tops estimates; clarifies path for key MS drug

May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

04 May 2018

Earnings vs. Estimates